Credit Suisse’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-213,914
| Closed | -$5.16M | – | 3326 |
|
|
2023
Q1 | $5.16M | Buy |
213,914
+124,144
| +138% | +$1.56M | 0.01% | 1289 |
|
|
2022
Q4 | $949K | Buy |
89,770
+54,093
| +152% | +$436K | ﹤0.01% | 2379 |
|
|
2022
Q3 | $160K | Buy |
35,677
+346
| +1% | +$1.58K | ﹤0.01% | 3319 |
|
|
2022
Q2 | $140K | Sell |
35,331
-1,749
| -5% | -$8.29K | ﹤0.01% | 3449 |
|
|
2022
Q1 | $271K | Sell |
37,080
-1,081
| -3% | -$6.46K | ﹤0.01% | 3268 |
|
|
2021
Q4 | $214K | Buy |
38,161
+2,454
| +7% | +$15.6K | ﹤0.01% | 4251 |
|
|
2021
Q3 | $227K | Buy |
35,707
+4,541
| +15% | +$29.2K | ﹤0.01% | 4189 |
|
|
2021
Q2 | $262K | Sell |
31,166
-4,609
| -13% | -$37.2K | ﹤0.01% | 4172 |
|
|
2021
Q1 | $375K | Sell |
35,775
-11,839
| -25% | -$167K | ﹤0.01% | 3920 |
|
|
2020
Q4 | $807K | Buy |
47,614
+23,374
| +96% | +$350K | ﹤0.01% | 3484 |
|
|
2020
Q3 | $311K | Buy |
24,240
+493
| +2% | +$6.23K | ﹤0.01% | 3637 |
|
|
2020
Q2 | $335K | Buy |
23,747
+1,927
| +9% | +$24.3K | ﹤0.01% | 3524 |
|
|
2020
Q1 | $200K | Sell |
21,820
-101,948
| -82% | -$1.31M | ﹤0.01% | 3651 |
|
|
2019
Q4 | $1.84M | Buy |
+123,768
| New | +$1.1M | ﹤0.01% | 2667 |
|
Other funds holding PRVB
Credit Suisse's PRVB Position: Q2 2023 in Review
Credit Suisse sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 213,914 shares — an estimated $5.16M sold.
Credit Suisse first reported a position in PRVB in Q4 2019 and held it in 14 quarters. The position peaked at $5.16M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Credit Suisse reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Credit Suisse sold 213,914 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $5.16M.
- Credit Suisse first reported a position in Provention Bio, Inc. Common Stock in Q4 2019 and held it in 14 quarters.
- Credit Suisse's Provention Bio, Inc. Common Stock position peaked at $5.16M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.